Utrecht University (Netherlands)
The Utrecht Pharmacoepidemiology Group is part of the Utrecht Institute for Pharmaceutical Sciences of the Utrecht University and is one of the leading academic groups in the world in the interface between pharmacoepidemiology, pharmacovigilance and drug innovation. The profile of the group includes new methods on drug channelling, exposure ascertainment, rare events, adjustment for confounding, record linkage, pharmacogenetics and implications for public health and weighing of benefits and drugs that are already on the market. More information can be found at www.uu.nl/en/research/pharmacoepidemiology-and-clinical-pharmacology.
Aarhus University Hospital (Denmark)
The Research Unit at Aarhus University Hospital has extensive experience in pharmaco-epidemiology including analyses of patients with diabetes and outcomes in patients treated with various anti-diabetic medications. All participants are trained specialists in endocrinology and thus have extensive clinical and research experience with patients with diabetes. Furthermore, this partner possesses extensive experience in working with Danish register data from all available sources. More information can be found at www.auh.dk.
Norwegian Institute of Public Health (Norway)
The Department of Pharmacoepidemiology at the Norwegian Institute of Public Health (NIPH) is running the nationwide Norwegian Prescription Database (NorPD). The research unit has access to and wide experience in handling and analyzing data from the different population-based data sources (health registries and comprehensive health surveys) in Norway. In addition, NIPH is running other nationwide health registries and comprehensive health surveys which may be linked to NorPD. The WHO Collaborating Centre for Drug Statistics Methodology, which classifies drug substances according to the ATC system and assigns defined daily doses (DDDs), is also a part of the department. More information can be found at www.fhi.no.
Karolinska Institute (Sweden)
The Centre for Pharmacoepidemiology performs pharmacoepidemiological research and provides expert knowledge and consultation on pharmacoepidemiology to society, authorities and industry. It is located at the Clinical Epidemiology Unit at the Department of Medicine at Karolinska Institute, Stockholm, Sweden. It includes 15 senior researchers with experiences in epidemiology, pharmacoepidemiology, biostatistics, pharmacovigilance and drug utilisation. The centre has taken an active part in the creation of European and Nordic networks (ENCePP and NorPEN). More information can be found at www.karolinska.se.
University of Tampere (Finland)
Tampere School of Public Health (TSPH) is the largest public health school in Finland. The school is responsible for the master’s programmes in public health and health sciences. The department of epidemiology has been an essential component within the school since the beginning and it has currently two full-time professors and a senior assistant professor, as well as three-part time professors. Annually, 5-10 PhD degrees are completed in the discipline. Cancer epidemiology is a prominent field with the department, with a long tradition of close collaboration with the Finnish Cancer Registry including shared positions. More information can be found at www.uta.fi.
University of Helsinki (Finland)
The University of Helsinki has the widest range of disciplines in Finland. The number of faculties is eleven. The University concentrates on high-level scientific research and researcher education. Scientific research is also the basis of the teaching provided by the University. The University has strong international connections. It has some 80 cooperation agreements with universities on different continents. The University researchers are in great demand as experts in international scientific communities, meetings and publications. Besides Helsinki, the University has operations at 20 localities throughout Finland. More information can be found at www.helsinki.fi/university.
Netherlands Cancer Institute (Netherlands)
The Netherlands Cancer Institute (NKI) is the only Dutch Cancer Centre combining hospital and research laboratories in a single independent organisation. The institute has a strong translational research programme. Support facilities include a comprehensive patient and tumour registry, biometrics, a microarray facility, a core facility Molecular Pathology and biobanking, and confocal and digital analysis facilities. The division of Pathology, including the subdivisions of Molecular Pathology and Psychosocial research and Epidemiology has a long standing interest and experience in translational research. The Department of Epidemiology focuses on the aetiology of hormone-related female cancers , the long-term adverse effects of cancer treatment and on gene-environment interactions in the aetiology of breast cancer. The Pathology department and the subdivision of molecular pathology have extensive experience with tumour profiling by gene- expression micro-array and CGH. More information can be found at www.nki.nl.